Amicus Therapeutics (NASDAQ: FOLD) and Impax Laboratories (NASDAQ:IPXL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Institutional & Insider Ownership
83.6% of Impax Laboratories shares are held by institutional investors. 3.4% of Amicus Therapeutics shares are held by insiders. Comparatively, 3.3% of Impax Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Amicus Therapeutics and Impax Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Amicus Therapeutics and Impax Laboratories’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Amicus Therapeutics||$16.28 million||125.55||-$186.93 million||($1.47)||-8.45|
|Impax Laboratories||$812.82 million||1.63||$144.42 million||($8.07)||-2.21|
Impax Laboratories has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Impax Laboratories, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Amicus Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Impax Laboratories has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
This is a breakdown of recent recommendations for Amicus Therapeutics and Impax Laboratories, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amicus Therapeutics currently has a consensus target price of $14.58, indicating a potential upside of 17.42%. Impax Laboratories has a consensus target price of $19.57, indicating a potential upside of 9.95%. Given Amicus Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Amicus Therapeutics is more favorable than Impax Laboratories.
Amicus Therapeutics beats Impax Laboratories on 7 of the 13 factors compared between the two stocks.
About Amicus Therapeutics
Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.
About Impax Laboratories
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
What are top analysts saying about Amicus Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amicus Therapeutics Inc. and related companies.